By InvitationPhase 3

Protest Trial: TXA vs Saline

United States94 participantsStarted 2024-04-16

Plain-language summary

To determine if endobronchial (topical) tranexamic acid used prophylactically prior to performing transbronchial biopsies in lung transplant recipients reduces bleeding risk.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Single or double lung transplant recipients
✓. Patients \>18 years old
✓. Willingness and ability to sign an informed consent for study participation

Exclusion criteria

✕. Platelet count (\<50k/uL)
✕. INR (\>1.6)
✕. Active bleeding
✕. Decompensated liver disease
✕. History of uremic bleeding or BUN \>50
✕. Severe pulmonary hypertension (mean PA pressure \>40 mmHg on RHC or estimated PA systolic pressure \>62 mmHg on TTE within one year of procedure)
✕. Known bleeding disorder
✕. Allergy to TXA

What they're measuring

Bleeding Risk

Timeframe: up to 1 hour

Trial details

NCT IDNCT06422273

SponsorCorewell Health West

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06-30

View on ClinicalTrials.gov More Lung Transplant trials